|
Phase IV open study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK)Biologicals live attenuated Measles-Mumps-Rubella (MMR) vaccine when given to healthy children at the age of 12 to 18months in Singapore. |
Measles, Mumps, Rubella Vaccine |
209762/147 (MeMuRu-147) |
NCT00388440 |
Measles; Mumps; Rubella |
Phase 4 |
|
|
|
|
An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. |
June 2015 |